Introduction: Several diseases with follicular occlusion have been described in HIV-infected patients and can appear isolated or associated with each other in an independent disease named ‘HIV-associated follicular syndrome’. Worsening of cutaneous lesions during the course of infection in patients with previous acne vulgaris, late onset or severe forms of acne have been reported in HIV-infected patients. Patients and Methods: A prospective study of 335 HIV-infected patients was performed in our hospital. A meticulous dermatological exploration in all patients was made, and multiple data were stored into a Microsoft Access 97 program. Patients diagnosed as having acne were considered separately, and we studied their characteristics. A statistical analysis with SPSS 9.0 (Statistical Package for the Social Sciences) was performed. Results: Thirty-six patients (10.8%) were diagnosed as having acne. Papulopustular lesions were the most frequent clinical presentation. Most lesions were localized on the face or on the back, and 80% of patients had mild to moderate acne; 40% of them required no treatment and the remainder was treated with topical measures, oral antibiotics and isotretinoin. 85% of cases reported the onset of acne during adolescence or before HIV infection and without any relationship with this disease. No relation between acne intensity and stage of HIV infection was observed. A multivariate analysis showed that the most important variable was age. Discussion: In contrast to previous reports, no greater intensity or modifications in acne lesions were observed in our HIV-infected patients during the course of the disease. In the majority of cases, cutaneous lesions started before HIV infection, during adolescence, and the most important factor for suffering from acne was young age. In contrast to data reported in the literature, no relation of acne lesions to CD4 lymphocyte count or AIDS case criteria was found in our patients. Conclusions: Acne in HIV-infected patients has characteristics similar to those in non-HIV-infected patients. The age is the most important factor for the appearance of lesions that usually develop during adolescence. Acne lesions are not modified by HIV infection, and no relationship with the severity of HIV infection has been observed.

Keywords:
Acne, Acquired immunodeficiency syndrome, Human immunodeficiency virus infection, Follicular occlusion
1.
Kwon PS, Maurer T, LeBoit PE, Aly R, Berger TG: Hormone-induced acneiform eruption in human immunodeficiency virus disease. Arch Dermatol 1998;134:374–376.
2.
Cohen SJ, Dicken CH: Generalized lichen spinulosus in an HIV-positive man. J Am Acad Dermatol 1991;25:116–118.
3.
Resnick SD, Murrell DF, Woosley J: Acne conglobata and a generalized lichen spinulosus-like eruption in a man seropositive for human immunodeficiency virus. J Am Acad Dermatol 1992;26:1013–1014.
4.
Blauvelt A, Nahass GT, Pardo RP, Kerdel FA: Pityriasis rubra pilaris and HIV infection. J Am Acad Dermatol 1991;24:703–705.
5.
Misery L, Faure M, Claudy A: Pityriasis rubra pilaris and human immunodeficiency virus infection – Type 6 pityriasis rubra pilaris? Br J Dermatol 1996;135:1008–1009.
6.
Resnick SD, Murrell DF, Woosley JT: Pityriasis rubra pilaris, acne conglobata, and elongated follicular spines: An HIV-associated follicular syndrome? J Am Acad Dermatol 1993;29:283–284.
7.
Sánchez-Regaña M, Fuentes CG, Creus L, Salleras M, Umbert P: Pityriasis rubra pilaris and HIV infection: A part of the spectrum of HIV-associated follicular syndrome. Br J Dermatol 1995;133:818–819.
8.
Jiménez J, González CM, López MJ, Martín González J, Granados Cerreño R: Síndrome de oclusión folicular en una paciente con infección VIH. Actas Dermosifiliogr 1997;88(suppl 2):71–72.
9.
Yar´mov N, Gachev N, Petkov K: Case of an HIV-patient with advanced form of perianal hidradenitis. Khirurgiia (Sofia) 2000;56:54–55.
10.
Smith KJ, Skelton HG, Yeager J, Ledsky R, McCarthy W, Bexter D, Turiansky GW, Wagner KF, Turiansky G: Cutaneous findings in HIV-1-positive patients: A 42-month prospective study. J Am Acad Dermatol 1994;31:746–754.
11.
Teillac D, Weber MJ, Lowenstein W, De Prost Y: Acné au survector. Ann Dermatol Vénéréol 1988;115:1183–1184.
12.
Martin AG, Weaver CC, Cockerell CJ, Berger TG: Pityriasis rubra pilaris in the setting of HIV-infection: Clinical behaviour and association with explosive cystic acne. Br J Dermatol 1992;126:617–620.
13.
Vigano A, Manzoni P, Riva S, Brambilla P, Ferrazzi E, Marzi MM: Hyperinsulinemia induced by highly active antiretroviral therapy in an adolescent with polycystic ovary syndrome who was infected with human immunodeficiency virus. Fertil Steril 2003;79:422–423.
14.
Garcia-Silva J, Almagro M, Peña-Penabad C, Fonseca E: Indinavir-induced retinoid-like effects: Incidence, clinical features and management. Drug Saf 2002;25:993–1003.
15.
Koreck A, Pivarcsi A, Dobozy A, Kemény L: The role of innate immunity in the pathogenesis of acne. Dermatology 2003;206:96–105.
16.
Dreno B, Poli F: Epidemiology of acne. Dermatology 2003;206:7–10.
17.
Jansen T, Plewig G: Acne inversa. Int J Dermatol 1998;37:96–100.
18.
Fonseca Capdevila E: Acné juvenil; in Fonseca Capdevila E (ed): Dermatología Pediátrica. Madrid, Aula Médica, 1999, pp 96–100.
19.
Fearfield LA, Rowe A, Francis N, Bunker CB, Staughton R: Itchy folliculitis and human immunodeficiency virus infection: Clinicopathological and immunological features, pathogenesis and treatment. Br J Dermatol 1999;141:3–11.
20.
Harms M, Péchère M, Krischer J, Studer E, Saurat JH: Oral isotretinoin in HIV-positive women with acne: Report of three cases. Dermatology 1998;196:163–164.
21.
Sass JO, Padberg J: Human isotretinoin metabolism during indinavir therapy. AIDS Res Hum Retroviruses 2000;16:1451–1452.
22.
Chirgwin KD, Feldman J, Muneyyirci-Delale O, Landesman S, Minkoff H: Menstrual function in human immunodeficiency virus-infected women without acquired immunodeficiency syndrome. J Acquir Immune Defic Syndr Hum Retrovirol 1996;12:489–494.
© 2005 S. Karger AG, Basel
2005
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.